Bathi resik saben saham sajrone 12 wulan pungkasan: Taysha Gene Therapies Inc (TSHA)

Taysha Gene Therapies focuses on innovative treatments for CNS pathologies, aiming to transform the therapy of genetic brain defects. Positive test results allow for the scaling of production, reducing the impact of fixed laboratory costs. Progress on the TSHA-102 drug and its FDA orphan drug status provide access to a massive market. The company's TTM net income per share visualizes the evolution of fundamental parameters, while the -0.44 metric serves as the target level.
Rincian metrik keuangan lan pasar Taysha (TSHA)

This indicator measures the rolling annual net income per share, which eliminates reporting time lags and allows for an accurate assessment of current business profitability. An analysis of the TTM fundamental earnings per share, combined with the high technological barrier to entry in the Rett syndrome gene therapy segment, confirms the resilience of the Taysha Gene Therapies (TSHA) scientific platform against competitors.